MannKind Corporation

Health Care · Biotechnology
Data updated Nov 22, 2026Money ledger: 2 records from 1 sourceFiled 2Full reportReport a mistake
Lately:3 news stories in 90 daysFollow changes →

Facts

as of Nov 22, 2026

Drawing on the legacy of innovator and humanitarian Alfred E. Mann, our team of passionate scientists, researchers, and professionals develops cutting-edge therapeutic products and technologies that help people take control of their health and live—fully humann.

Legal name
MANNKIND CORP
Employees
501-1000estimated range
Listing
NASDAQ: MNKD
Register numbers
EIN 133607736
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

MannKind Corporation has $227.7M paid in by investors, lenders and donors.

$227.7MPaid in
Money innewest first
Loan or credit · Blackstone
Jun 2026 · Loan from Blackstone Secured Lending Fund
$138.9MPaid
Loan or credit · Blackstone
Jun 2026 · Loan from Blackstone Private Credit Fund
$88.8MPaid
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".

MannKind Corporation operates through 1 legal entity in 1 country.

Legal entities1 in 1 country
MANNKIND CORP
operator · US EIN 133607736
US
Holders and shares as each register or filing states them.

Products

Products →

MannKind Corporation has 59 clinical trials on record, 2 under way. MannKind Corporation paid US doctors and teaching hospitals $527k in 2025, and $2.3M for research (CMS Open Payments).

444 a monthWikipedia readersMannKind Corporation · -38% y/y
Clinical trials
Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis
phase 2 · under way · 153 participants · Idiopathic Pulmonary Fibrosis; Idiopathic Pulmonary Fibrosis (IPF)
May 2026
INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes
phase 2 · under way · 100 participants · Type 1 Diabetes Mellitus
Feb 2026
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis
phase 1 · completed · 27 participants · Idiopathic Pulmonary Fibrosis (IPF)
Dec 2025
Wikipedia readersen.wikipedia.org
Nov 2024Oct 2026 · 444
Source: each app’s App Store and Google Play page (an app counts as the company’s when its developer site is on the company’s domain); the products its own site names.

MannKind Corporation: 13 research papers in five years, $20k of EU lobbying in 2026.

Legal entity active
MANNKIND CORP
Not checked
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
US lobbying
2026 · JEFFREY J. KIMBELL & ASSOCIATES, INC. $20,000
$20k
Patents
37
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Newsroom
Sources: the outlets named on each headline, each story once